ObsEva’s second uterine fibroids PhIII comes through, sending some investors to the hills

Jason Mast

Editor

In the three-company race to develop a new uterine fibroid treatment, ObsEva long lagged behind AbbVie and Myovant. Still, they hoped that better efficacy � …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ObsEva’s second uterine fibroids PhIII comes through, sending some investors to the hills

Jason Mast

Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Boehringer’s updated results in HER2-mutated lung cancer impress

Novavax responds to FDA’s trial ask, with Covid vaccine strain updates under scrutiny

GSK’s checkpoint blocker Jemperli cures biomarker-driven rectal cancer

Merck KGaA to buy rare cancer biotech SpringWorks for $3.9B

European regulators recommend new drugs from Vertex, Amgen and Jazz

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

Ob­sE­va’s sec­ond uter­ine fi­broids PhI­II comes through, send­ing some in­vestors to the hills

Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

ObsEva’s second uterine fibroids PhIII comes through, sending some investors to the hills